Acrux Limited (ASX:ACR)
Australia
· Delayed Price · Currency is AUD 0.0130
-0.0005 (-3.70%)
Mar 9, 2026, 8:02 AM AEST
Acrux Revenue
Acrux had revenue of 1.74M AUD in the half year ending December 31, 2025, a decrease of -60.54%. This brings the company's revenue in the last twelve months to 2.81M, up 250.37% year-over-year. In the fiscal year ending June 30, 2025, Acrux had annual revenue of 1.19M, down -76.63%.
Revenue (ttm)
2.81M
Revenue Growth
+250.37%
P/S Ratio
1.97
Revenue / Employee
65.35K
Employees
43
Market Cap
5.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.19M | -3.90M | -76.63% |
| Jun 30, 2024 | 5.09M | -3.34M | -39.60% |
| Jun 30, 2023 | 8.43M | 6.71M | 390.34% |
| Jun 30, 2022 | 1.72M | 382.00K | 28.57% |
| Jun 30, 2021 | 1.34M | 84.00K | 6.70% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nexalis Therapeutics | 761.96K |
| Zelira Therapeutics | 656.00 |
| Vectus Biosystems | 89.96K |
| Biotron | -868.00 |
| Chimeric Therapeutics | 9.75M |
| Anatara Lifesciences | 623.76K |
| Invex Therapeutics | 229.08K |
| Immuron | 7.48M |